FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
Peptide chromatogram analysis is where a stated purity specification becomes traceable analytical evidence. A vial label reading >99% HPLC purity is useful only when the underlying chromatogram, integration method, run conditions, and batch-specific documentation support that figure. For researchers evaluating research-grade peptides, the chromatogram is not a decorative attachment to a certificate of analysis. It is primary quality-control data.
A clean trace can indicate a well-controlled material, but it does not independently establish peptide identity, absolute purity, or suitability for every experimental design. Those conclusions require a method-aware review of the chromatogram alongside mass spectrometry data, manufacturing controls, and the complete COA.
> Compliance Notice
> FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. Peptide materials discussed here are intended solely for legitimate laboratory research, analytical work, and in vitro or preclinical study workflows. They are not food, dietary supplements, drugs, or materials for personal use.
What a Peptide Chromatogram Shows
Most peptide COAs use reversed-phase high-performance liquid chromatography, commonly abbreviated RP-HPLC. In this method, the sample passes through a nonpolar stationary phase under a programmed mobile-phase gradient, often water and acetonitrile with a volatile acidic modifier. Components elute at different retention times based on hydrophobicity, molecular structure, and interaction with the column chemistry.
The resulting chromatogram plots detector response against retention time. For a UV method, the response commonly reflects absorbance near 214 to 220 nm, where peptide bonds produce a strong signal. Detection at 280 nm may provide additional context for sequences containing aromatic residues, but it is not a universal peptide assay wavelength.
A principal peak is usually assigned to the target peptide. Smaller peaks may represent deletion sequences, truncated material, oxidation products, diastereomeric species, residual synthesis-related components, or method artifacts. Their identity cannot be determined from retention time alone. A minor peak is an observation first, not a confirmed impurity assignment.
For example, a batch of BPC-157 is generally described by the 15-residue sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a calculated average molecular weight near 1419.5 Da. An HPLC peak at the expected retention window may be consistent with that material, but LC-MS confirmation of the expected molecular mass is needed to support identity.
How to Read Peptide Chromatogram Analysis Data
The first question is simple: does one dominant peak account for the stated area percentage? If a COA reports 99.0% HPLC purity, the integrated main peak should represent approximately 99.0% of the total included peak area under the stated method. The word “included” matters. Chromatography software can exclude peaks below a reporting threshold, and different integration settings can change the calculated percentage.
Review the Method Before Reviewing the Peak
A chromatogram without method parameters has limited value. At minimum, documentation should state the column chemistry and dimensions, mobile phases, gradient program, flow rate, column temperature, injection volume, UV wavelength, and sample concentration. Retention time has meaning only within that method.
A short gradient can compress multiple components into one broad or asymmetric peak. A longer, appropriately optimized gradient may reveal closely eluting variants that a fast screening method does not resolve. Neither approach is automatically wrong. The relevant question is whether the method is suitable for resolving likely process-related and degradation-related species for that peptide sequence.
Method suitability is commonly evaluated through system-suitability criteria. These may include retention-time repeatability, theoretical plates, tailing factor, and resolution between specified peaks. Resolution is especially informative when two adjacent peaks are present. A visually clean peak is not necessarily a fully resolved peak.
Inspect Peak Shape, Baseline, and Early Elution
A credible main peak should have a stable baseline and a reasonably symmetrical profile for the method used. Excessive fronting can point to overloading or sample-solvent mismatch. Tailing may arise from secondary interactions, column condition, or analyte behavior. Broad peaks can result from poor mass transfer, gradient conditions, column aging, or unresolved material.
Examine the full acquisition window rather than only the region around the main peak. Early-eluting signals may reflect salts, highly polar process components, or injection artifacts. Late-eluting peaks can indicate hydrophobic species or carryover. A cropped trace that omits these regions does not provide the same assurance as a complete chromatogram.
Baseline noise also needs context. Low-level detector fluctuation is normal. A drifting baseline, abrupt step changes, or recurring ghost peaks can complicate integration and should be accounted for before assigning a purity percentage.
Treat Area Percent as a Relative Measurement
Area-percent purity is a relative UV measurement, not an absolute mass balance. Different compounds can have different UV responses at the chosen wavelength. A 0.5% area peak is not automatically 0.5% by mass, and a chromatogram does not quantify non-UV-active material or every possible residual component.
For this reason, HPLC area percent is best interpreted as one component of a broader release package. Orthogonal testing can include LC-MS for molecular mass confirmation, moisture testing, residual-solvent analysis, counterion or acetate content where applicable, and microbial or endotoxin testing when a research workflow specifically requires those data.
What “>99% HPLC” Should Mean on a COA
A stated >99% HPLC result should be tied to a specific lot number, test date, method, and chromatogram. Generic charts reused across multiple lots do not provide batch-level verification. Researchers should expect the COA lot number to match the vial label and the documentation supplied for that material.
Look for a clear purity result, a labeled principal peak, and visible minor peaks where present. The report should identify the analytical laboratory or testing function and include an authorized review or release indication. Third-party verification adds value when the external report is traceable to the same lot and uses a defined method.
At Peptide Source, the relevant standard for a research-grade release decision is documentation that can be reviewed, not an unsupported purity claim. Manufacturer COAs, batch traceability, and additional third-party analytical verification provide stronger evidence together than any single graphic or marketing statement.
When the Chromatogram Needs More Investigation
A high main-peak area does not eliminate the need for follow-up. Additional review is warranted when the trace shows shoulders on the main peak, unexplained late peaks, broad baseline disturbance, inconsistent retention time, or integration boundaries that appear to omit visible signal.
Shoulders deserve particular attention. They can indicate partial co-elution, isomeric material, oxidation, or overload-related distortion. Re-injection at a lower concentration, a modified gradient, or an alternate stationary phase may clarify whether the feature is a separate component. LC-MS can then help determine whether a mass difference is present.
The same principle applies to lot-to-lot comparison. Small retention-time shifts may be normal when instruments, columns, or mobile-phase preparation vary within a validated method. Meaningful differences in peak shape, impurity pattern, or principal-peak area deserve investigation before material is treated as analytically comparable.
A Practical COA Review Workflow
Use the batch number as the starting point. Match it to the vial label, then confirm the peptide name, stated amount, molecular weight, and stated HPLC purity. Review the complete chromatogram and method conditions before relying on the area-percent result.
Next, compare the principal peak with the LC-MS identity result. For a peptide supplied as a salt, distinguish calculated peptide mass from the total vial mass, which may reflect counterion and water content. Finally, archive the COA, chromatogram, and any third-party report with the experimental record. This supports material traceability if later analytical questions arise.
Current analytical expectations are reflected in established compendial and validation frameworks, including USP <621> Chromatography, USP <1225> Validation of Compendial Procedures, and ICH Q2(R2) Validation of Analytical Procedures. These frameworks emphasize specificity, precision, accuracy where applicable, linearity, range, and detection capability. The exact validation package depends on whether the method is used for screening, release testing, stability indication, or impurity characterization.
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. Chromatographic data support analytical decisions in laboratory settings and do not authorize human use of any research peptide.
A chromatogram earns confidence when it is readable, batch-matched, method-defined, and supported by orthogonal identity data. Ask for the full record, preserve it with your lab files, and treat unexplained peaks as questions worth answering before research begins.